Vimarsana
Biggest News Aggregation in the World

Page 2 - Gene Correction News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Gene Correction. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Gene Correction Today - Breaking & Trending Today

Women's Giving Circle Awards $110,000 in Funding to U of A Programs - Vimarsana News

Women's Giving Circle Awards $110,000 in Funding to U of A Programs

Nine university programs were awarded a combined $110,000 from the Women’s Giving Circle.

Source: uark.edu
Chroma Medicine Presents Data Demonstrating Near-Complete, Durable In Vivo Silencing with Targeted Epigenetic Editors at 2023 ASGCT Annual Meeting - Vimarsana News

Chroma Medicine Presents Data Demonstrating Near-Complete, Durable In Vivo Silencing with Targeted Epigenetic Editors at 2023 ASGCT Annual Meeting

/PRNewswire/ -- Chroma Medicine, Inc., (Chroma) a genomic medicine company pioneering single-dose epigenetic editing therapeutics, today announced in vivo data...

Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results - Vimarsana News

Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results

Focused on Executing Three Strategic Pillars – Hematology, Immunology/Oncology and Genetic Diseases – Potential for Long-Term Pipeline Growth and Sustained Impact on Patient Lives ... | May 10, 2023

Ascidian Therapeutics to Present New Data From Its Lead Program Targeting ABCA4 Retinopathies at the ASGCT 2023 Annual Meeting - Vimarsana News

Ascidian Therapeutics to Present New Data From Its Lead Program Targeting ABCA4 Retinopathies at the ASGCT 2023 Annual Meeting

/PRNewswire/ -- Ascidian Therapeutics, a biotechnology company focused on treating human diseases by rewriting RNA, announced today that Head of Research...

EdiGene to Unveil Promising Preclinical POC Data for LEAPER™ 2.0-based in vivo RNA Editing Therapies - Vimarsana News

EdiGene to Unveil Promising Preclinical POC Data for LEAPER™ 2.0-based in vivo RNA Editing Therapies

BEIJING--(BUSINESS WIRE)--EdiGene, Inc., a clinical-stage biotechnology company focused on developing transformative gene-editing therapies, announced an oral presentation on the preclinical proof-of-concept (POC) data in non-human primate (NHP) model, including NHP disease model, for LEAPERTM 2.0-based in vivo RNA...